Vor Biopharma (VOR) Interest & Investment Income (2020 - 2026)

Vor Biopharma (VOR) has reported Interest & Investment Income for 7 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest & Investment Income rose 388.82% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $9.0 million (up 153.18% YoY), while the FY2025 annual figure was $5.9 million, up 37.39% from the prior year.
• Interest & Investment Income improved to $3.9 million in Q1 2026 per VOR's latest filing, from $2.8 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $3.9 million in Q1 2026 and bottomed at $63000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $1.4 million across 5 years, with a median of $1.2 million in 2024.
• Annual changes were most pronounced in 2023 — Interest & Investment Income surged 3057.14% — and 2024, when it plunged 67.85%.
• Vor Biopharma's Interest & Investment Income stood at $815000.0 in 2022, then jumped by 128.59% to $1.9 million in 2023, then slumped by 67.85% to $599000.0 in 2024, then jumped by 366.61% to $2.8 million in 2025, then soared by 40.79% to $3.9 million in 2026.
• Business Quant data shows VOR's Interest & Investment Income at $3.9 million in Q1 2026, $2.8 million in Q4 2025, and $1.7 million in Q3 2025.